Has nanotechnology led to improved therapeutic outcomes?

Drug Development and Industrial Pharmacy

Volumn 38, Issue 2, 2012, Pages 158-170

  Bosselmann, Stephanie ^a   Williams III, Robert O ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Drug targeting; Efficacy of nanoparticles; Nanotechnology; Oral delivery; Parenteral delivery; Poorly soluble drugs; Pulmonary delivery; Safety of nanoparticles

Indexed keywords

ALBUMIN; ANTINEOPLASTIC AGENT; APREPITANT; BUDESONIDE; CREMOPHOR; DEXAMETHASONE; DOXORUBICIN; FENOFIBRATE; FLUOROURACIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; ISONIAZID; ITRACONAZOLE; LOW DENSITY LIPOPROTEIN; MEGESTROL ACETATE; NANOBUDESONIDE; NANOCRYSTAL; NANOPARTICLE; PACLITAXEL; POLYGLACTIN; PYRAZINAMIDE; RAPAMYCIN; RIFAMPICIN; SEROTONIN 3 ANTAGONIST; SOLID LIPID NANOPARTICLE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANOREXIA; AREA UNDER THE CURVE; ASPERGILLUS FUMIGATUS; ASTHMA; BREAST CANCER; CACHEXIA; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CHEMOTHERAPY INDUCED EMESIS; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG MARKETING; DRUG SAFETY; DRUG SOLUBILITY; DRUG TARGETING; DRUG UPTAKE; DYSLIPIDEMIA; EPILEPTIC STATE; FIRST PASS EFFECT; FOOD DRUG INTERACTION; HEART ARREST; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; KIDNEY GRAFT REJECTION; LIPOPROTEIN BLOOD LEVEL; LUNG ALVEOLUS MACROPHAGE; LUNG ASPERGILLOSIS; LUNG CANCER; LUNG MYCOSIS; LUNG TUBERCULOSIS; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NANOTECHNOLOGY; NAUSEA; NEBULIZATION; NONHUMAN; OUTCOME ASSESSMENT; PARTICLE SIZE; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POWDER INHALER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; STEROID THERAPY; THERAPY EFFECT; THERMODYNAMICS; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; VASCULAR TUMOR;

DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; NANOTECHNOLOGY; PHARMACEUTICAL PREPARATIONS; SOLUBILITY;

EID: 84255171410     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2011.597764     Document Type: Review

References (125)

1. Merisko-Liversidge EM, Liversidge GG. (2008). Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol Pathol, 36:43-48.
2. Yih TC, Al-Fandi M. (2006). Engineered nanoparticles as precise drug delivery systems. J Cell Biochem, 97:1184-1190.
3. Rao GC, Kumar MS, Mathivanan N, Rao ME. (2004). Nanosuspensions as the most promising approach in nanoparticulate drug delivery systems. Pharmazie, 59:5-9. (Pubitemid 38129292)
4. United States Patent and Trademark Office. (2010). Nanotechnology- Class Definition. [Online] Available at: http://www.uspto.gov/ web/patents/ classification/uspc977/defs977.htm. Accessed on 29 October 2010.
5. Oberdörster G, Oberdörster E, Oberdörster J. (2005). Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect, 113:823-839. (Pubitemid 40984181)
6. Ferrari M. (2005). Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer, 5:161-171. (Pubitemid 40314948)
7. Hans ML, Lowman AM. (2002). Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid State Mat Sci 6:319-327. (Pubitemid 36238389)
8. Dunne A, Devane J, O'Hara T. (1999). The relationship between in vitro drug dissolution and in vivo absorption. J R Stat Soc Ser D-Stat 48:125-133.
9. Amidon GL, Lennern's H, Shah VP, Crison JR. (1995). A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res, 12:413-420.
10. FDA. (2000). Guidance for industry: waiver of in vivo bioavailability and bioequivalence studies for immediate release dosage forms based on a biopharmaceutical classification system. Center for Drug Evaluation and Research.
11. Muller RH, Junghanns JAH. (2006). Drug nanocrystals/ nanosuspensions for the delivery of poorly soluble drugs. In: Tochilin V (Ed.) Nanoparticulates as drug carriers. Imperial College Press, London, UK. 307-328.
12. Fahr A, Liu X. (2007). Drug delivery strategies for poorly watersoluble drugs. Expert Opin Drug Deliv, 4:403-416. (Pubitemid 47249138)
13. Hilden LR, Morris KR. (2004). Physics of amorphous solids. J Pharm Sci, 93:3-12. (Pubitemid 38087927)
14. Tang B, Cheng G, Gu JC, Xu CH. (2008). Development of solid selfemulsifying drug delivery systems: preparation techniques and dosage forms. Drug Discov Today, 13:606-612.
15. Huang L, Dong J. (2008). Formulation strategies and practice used for candidates with water-insoluble properties for toxicology, biology, and pharmacology studies in discovery support. In: Liu R (Ed.) Water-insoluble drug formulation. CPR Press, Boca Raton, USA. 113-132.
16. Noyes A, Whitney W. (1897). The rate of solution of solid substances in their own solutions, J Am Chem Soc 19: 930-934.
17. Bisrat M, Nystrom C. (1988). Physicochemical aspects of drug release.8. the relation between particle-size and surface specific dissolution rate in agitated suspensions. Int J Pharm 47:223-231.
18. Mosharraf M, Nystrom C. (1995). The effect of particle-size and shape on the surface specific dissolution rate of microsized practically insoluble drugs. Int J Pharm 122:35-47.
19. Junghanns JU, Müller RH. (2008). Nanocrystal technology, drug delivery and clinical applications. Int J Nanomedicine, 3:295-309.
20. Welling PG. (1977). Influence of food and diet on gastrointestinal drug absorption: a review. J Pharmacokinet Biopharm, 5:291-334. (Pubitemid 8151028)
21. Gu CH, Li H, Levons J, Lentz K, Gandhi RB, Raghavan K et al. (2007). Predicting effect of food on extent of drug absorption based on physicochemical properties. Pharm Res, 24:1118-1130. (Pubitemid 46798891)
22. Welling PG. (1996). Effects of food on drug absorption. Annu Rev Nutr, 16:383-415.
23. Lentz KA. (2008). Current methods for predicting human food effect. AAPS J, 10:282-288.
24. Keck CM, Müller RH. (2006). Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm, 62:3-16. (Pubitemid 41736019)
25. Elan Drug Technologies. (2010). Nanocrystal® Technology. commercialized Products. [Online] Available at: http:// www. elandrugtechnologies.com/nanocrystal-technology/ commercialised. Accessed on 17 October 2010.
26. Merisko-Liversidge E, Liversidge GG, Cooper ER. (2003). Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci, 18:113-120. (Pubitemid 36184748)
27. Vazquez EM. (2000). Sirolimus: A new agent for prevention of renal allograft rejection. Am J Health-Syst Pharm 57:437-448.
28. Simamora P, Alvarez JM, Yalkowsky SH. (2001). Solubilization of rapamycin. Int J Pharm, 213:25-29. (Pubitemid 32119459)
29. Gandhi PJ, Murthy ZVP. (2010). Kinetic study of ultrasonic antisolvent crystallization of sirolimus. Cryst Res Technol 45: 321-327.
30. Shen LJ, Wu FL. (2007). Nanomedicines in renal transplant rejection-focus on sirolimus. Int J Nanomedicine, 2:25-32.
31. Lampen A, Zhang Y, Hackbarth I, Benet LZ, Sewing KF, Christians U. (1998). Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine. J Pharmacol Exp Ther, 285:1104-1112. (Pubitemid 28277909)
32. Zimmerman JJ, Ferron GM, Lim HK, Parker V. (1999). The effect of a high-fat meal on the oral bioavailability of the immunosuppressant sirolimus (rapamycin). J Clin Pharmacol, 39:1155-1161. (Pubitemid 30644018)
33. Mathew TH, Van Buren C, Kahan BD, Butt K, Hariharan S, Zimmerman JJ. (2006). A comparative study of sirolimus tablet versus oral solution for prophylaxis of acute renal allograft rejection. J Clin Pharmacol, 46:76-87. (Pubitemid 43021716)
34. Majumdar AK, Howard L, Goldberg MR, Hickey L, Constanzer M, Rothenberg PL et al. (2006). Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. J Clin Pharmacol, 46:291-300. (Pubitemid 43260316)
35. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R et al.; Aprepitant Protocol 052 Study Group. (2003). The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group. J Clin Oncol, 21:4112-4119. (Pubitemid 46606178)
36. Wu Y, Loper A, Landis E, Hettrick L, Novak L, Lynn K et al. (2004). The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int J Pharm, 285:135-146. (Pubitemid 39361543)
37. Olver I, Shelukar S, Thompson KC. (2007). Nanomedicines in the treatment of emesis during chemotherapy: focus on aprepitant. Int J Nanomedicine, 2:13-18. (Pubitemid 46901776)
38. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A et al.; Aprepitant Protocol 054 Study Group. (2003). Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer, 97:3090-3098. (Pubitemid 36676265)
39. Tziomalos K, Athyros VG. (2006). Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review. Int J Nanomedicine, 1:129-147.
40. Guay DR. (1999). Micronized fenofibrate: a new fibric acid hypolipidemic agent. Ann Pharmacother, 33:1083-1103. (Pubitemid 29489991)
41. Guichard JP, Blouquin P, Qing Y. (2000). A new formulation of fenofibrate: suprabioavailable tablets. Curr Med Res Opin, 16:134-138. (Pubitemid 30426776)
42. Keating GM, Ormrod D. (2002). Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia. Drugs, 62:1909-1944.
43. Stamm A, Seth P. (2003). Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it. US Patent No. 6589552.
44. Maciejewski S, Hilleman D. (2008). Effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemia. Pharmacotherapy, 28:570-575. (Pubitemid 351620025)
45. Femia RA, Goyette RE. (2005). The science of megestrol acetate delivery: potential to improve outcomes in cachexia. Biodrugs, 19:179-187. (Pubitemid 40994233)
46. Berenstein EG, Ortiz Z. (2005). Megestrol acetate for the treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev, CD004310.
47. Zhang ZB, Shen ZG, Wang JX, Zhao H, Chen JF, Yun J. (2009). Nanonization of megestrol acetate by liquid precipitation. Ind Eng Chem Res 48:8493-8499.
48. Hovey D, Pruitt J, Ryde T. (2005). Nanoparticulate megestrol formulations. US Patent Application. Pub.No. US 2005/0233001 A1.
49. Graham KK, Mikolich DJ, Fisher AE, Posner MR, Dudley MN. (1994). Pharmacologic evaluation of megestrol acetate oral suspension in cachectic AIDS patients. J Acquir Immune Defic Syndr, 7:580-586. (Pubitemid 24157666)
50. Par Pharmaceuticals. Par Pharmaceuticals Announces FDA Approval of Megace ES for Anorexia, Cachexia, or an Unexplained, Significant Weight Loss in Patients with a Diagnosis of AIDS. [Online] Available at: http://www.parpharm. com/generics/index. Accessed on 19 October 2010.
51. Deschamps B, Musaji N, Gillespie JA. (2009). Food effect on the bioavailability of two distinct formulations of megestrol acetate oral suspension. Int J Nanomedicine, 4:185-192.
52. Agu RU, Ugwoke MI, Armand M, Kinget R, Verbeke N. (2001). The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir Res, 2:198-209. (Pubitemid 34187927)
53. Suarez S, Hickey AJ. (2000). Drug properties affecting aerosol behavior. Respir Care, 45:652-666. (Pubitemid 30484805)
54. Gehr P, Bachofen M, Weibel ER. (1978). The normal human lung: ultrastructure and morphometric estimation of diffusion capacity. Respir Physiol, 32:121-140. (Pubitemid 8295531)
55. Laube BL. (2005). The expanding role of aerosols in systemic drug delivery, gene therapy, and vaccination. Respir Care, 50:1161-1176.
56. Sweeney TD, Brain JD. (1991). Pulmonary deposition: determinants and measurement techniques. Toxicol Pathol, 19:384-397.
57. Courrier HM, Butz N, Vandamme TF. (2002). Pulmonary drug delivery systems: recent developments and prospects. Crit Rev Ther Drug Carrier Syst, 19:425-498. (Pubitemid 36314479)
58. Labiris NR, Dolovich MB. (2003). Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol, 56:588-599. (Pubitemid 37491710)
59. Byron PR. (1986). Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. J Pharm Sci, 75:433-438. (Pubitemid 16083635)
60. Jaques PA, Kim CS. (2000). Measurement of total lung deposition of inhaled ultrafine particles in healthy men and women. Inhal Toxicol, 12:715-731.
61. Henning A, Hein S, Schneider M, Bur M, Lehr CM.(2010). Pulmonary drug delivery: medicines for inhalation. In: Schaefer- Korting M (Ed.) Drug delivery. Springer, Berlin, Heidelberg, Germany. 176.
62. Tsapis N, Bennett D, Jackson B, Weitz DA, Edwards DA. (2002). Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc Natl Acad Sci USA, 99:12001-12005.
63. Sham JO, Zhang Y, Finlay WH, Roa WH, Löbenberg R. (2004). Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung. Int J Pharm, 269:457-467. (Pubitemid 38045308)
64. Hadinoto K, Phanapavudhikul P, Kewu Z, Tan RBH. (2006). Novel formulation of large hollow nanoparticles aggregates as potential carriers in inhaled delivery of nanoparticulate drugs. Ind Eng Chem Res 45:3697-3706. (Pubitemid 43812807)
65. Hadinoto K, Zhu K, Tan RB. (2007). Drug release study of large hollow nanoparticulate aggregates carrier particles for pulmonary delivery. Int J Pharm, 341:195-206. (Pubitemid 47088103)
66. Hofmann W, Asgharian B. (2003). The effect of lung structure on mucociliary clearance and particle retention in human and rat lungs. Toxicol Sci, 73:448-456. (Pubitemid 36701747)
67. Schürch S, Gehr P, Im Hof V, Geiser M, Green F. (1990). Surfactant displaces particles toward the epithelium in airways and alveoli. Respir Physiol, 80:17-32. (Pubitemid 20160258)
68. Geiser M. (2010). Update on macrophage clearance of inhaled micro- and nanoparticles. J Aerosol Med Pulm Drug Deliv, 23:207-217.
69. Takenaka S, Karg E, Kreyling WG, Lentner B, Möller W, Behnke- Semmler M et al. (2006). Distribution pattern of inhaled ultrafine gold particles in the rat lung. Inhal Toxicol, 18:733-740.
70. Semmler-Behnke M, Takenaka S, Fertsch S, Wenk A, Seitz J, Mayer P et al. (2007). Efficient elimination of inhaled nanoparticles from the alveolar region: evidence for interstitial uptake and subsequent reentrainment onto airways epithelium. Environ Health Perspect, 115:728-733. (Pubitemid 46785042)
71. Geiser M, Casaulta M, Kupferschmid B, Schulz H, Semmler-Behnke M, Kreyling W. (2008). The role of macrophages in the clearance of inhaled ultrafine titanium dioxide particles. Am J Respir Cell Mol Biol, 38:371-376. (Pubitemid 351567707)
72. Hoeben BJ, Burgess DS, McConville JT, Najvar LK, Talbert RL, Peters JI et al. (2006). In vivo efficacy of aerosolized nanostructured itraconazole formulations for prevention of invasive pulmonary aspergillosis. Antimicrob Agents Chemother, 50:1552-1554.
73. McConville JT, Overhoff KA, Sinswat P, Vaughn JM, Frei BL, Burgess DS et al. (2006). Targeted high lung concentrations of itraconazole using nebulized dispersions in a murine model. Pharm Res, 23:901-911. (Pubitemid 43781398)
74. Vaughn JM, McConville JT, Burgess D, Peters JI, Johnston KP, Talbert RL et al. (2006). Single dose and multiple dose studies of itraconazole nanoparticles. Eur J Pharm Biopharm, 63:95-102. (Pubitemid 43776206)
75. Vaughn JM, Wiederhold NP, McConville JT, Coalson JJ, Talbert RL, Burgess DS et al. (2007). Murine airway histology and intracellular uptake of inhaled amorphous itraconazole. Int J Pharm, 338:219-224. (Pubitemid 46777243)
76. Garbuzenko OB, Saad M, Pozharov VP, Reuhl KR, Mainelis G, Minko T. (2010). Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance. Proc Natl Acad Sci USA, 107:10737-10742.
77. Brigger I, Dubernet C, Couvreur P. (2002). Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev, 54:631-651. (Pubitemid 35247520)
78. Hitzman CJ, Wattenberg LW, Wiedmann TS. (2006). Pharmacokinetics of 5-fluorouracil in the hamster following inhalation delivery of lipid-coated nanoparticles. J Pharm Sci, 95:1196-1211. (Pubitemid 43874436)
79. Azarmi S, Tao X, Chen H, Wang Z, Finlay WH, Löbenberg R et al. (2006). Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles. Int J Pharm, 319:155-161. (Pubitemid 44051806)
80. Sharma S, White D, Imondi AR, Placke ME, Vail DM, Kris MG. (2001). Development of inhalational agents for oncologic use. J Clin Oncol, 19:1839-1847. (Pubitemid 32230887)
81. Otterson GA, Villalona-Calero MA, Sharma S, Kris MG, Imondi A, Gerber M et al. (2007). Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs. Clin Cancer Res, 13:1246-1252. (Pubitemid 46424066)
82. Kraft WK, Steiger B, Beussink D, Quiring JN, Fitzgerald N, Greenberg HE et al. (2004). The pharmacokinetics of nebulized nanocrystal budesonide suspension in healthy volunteers. J Clin Pharmacol, 44:67-72. (Pubitemid 38005095)
83. Sung JC, Pulliam BL, Edwards DA. (2007). Nanoparticles for drug delivery to the lungs. Trends Biotechnol, 25:563-570. (Pubitemid 350138179)
84. Chono S, Tanino T, Seki T, Morimoto K. (2007). Uptake characteristics of liposomes by rat alveolar macrophages: influence of particle size and surface mannose modification. J Pharm Pharmacol, 59:75-80. (Pubitemid 46133045)
85. du Toit LC, Pillay V, Danckwerts MP. (2006). Tuberculosis chemotherapy: current drug delivery approaches. Respir Res, 7:118.
86. Pandey R, Sharma A, Zahoor A, Sharma S, Khuller GK, Prasad B. (2003). Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother, 52:981-986. (Pubitemid 38008419)
87. Sharma A, Sharma S, Khuller GK. (2004). Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J Antimicrob Chemother, 54:761-766. (Pubitemid 39386728)
88. Pandey R, Khuller GK. (2005). Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis (Edinb), 85:227-234. (Pubitemid 40805619)
89. Müller RH, M'der K, Gohla S. (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm, 50:161-177. (Pubitemid 30326695)
90. Mansour HM, Rhee YS, Wu X. (2009). Nanomedicine in pulmonary delivery. Int J Nanomedicine, 4:299-319.
91. Pandey R, Khuller GK. (2005). Antitubercular inhaled therapy: opportunities, progress and challenges. J Antimicrob Chemother, 55:430-435. (Pubitemid 40542580)
92. Kawashima Y, Yamamoto H, Takeuchi H, Fujioka S, Hino T. (1999). Pulmonary delivery of insulin with nebulized DL-lactide/glycolide copolymer (PLGA) nanospheres to prolong hypoglycemic effect. J Control Release, 62:279-287. (Pubitemid 29486508)
93. Zhang Q, Shen Z, Nagai T. (2001). Prolonged hypoglycemic effect of insulin-loaded polybutylcyanoacrylate nanoparticles after pulmonary administration to normal rats. Int J Pharm, 218:75-80. (Pubitemid 32406158)
94. Renwick LC, Brown D, Clouter A, Donaldson K. (2004). Increased inflammation and altered macrophage chemotactic responses caused by two ultrafine particle types. Occup Environ Med, 61:442-447. (Pubitemid 38655947)
95. Oberdörster G. (1997). Pulmonary carcinogenicity of inhaled particles and the maximum tolerated dose. Environ Health Perspect, 105 Suppl 5:1347-1355.
96. Oberdörster G, Ferin J, Gelein R, Soderholm SC, Finkelstein J. (1992). Role of the alveolar macrophage in lung injury: studies with ultrafine particles. Environ Health Perspect, 97:193-199.
97. Renwick LC, Donaldson K, Clouter A. (2001). Impairment of alveolar macrophage phagocytosis by ultrafine particles. Toxicol Appl Pharmacol, 172:119-127. (Pubitemid 32373134)
98. Donaldson K, Stone V, Clouter A, Renwick L, MacNee W. (2001). Ultrafine particles. Occup Environ Med, 58:211-6, 199.
99. Nikula KJ. (2000). Rat lung tumors induced by exposure to selected poorly soluble nonfibrous particles. Inhal Toxicol, 12:97-119. (Pubitemid 30081165)
100. Borm PJ, Schins RP, Albrecht C. (2004). Inhaled particles and lung cancer, part B: paradigms and risk assessment. Int J Cancer, 110:3-14. (Pubitemid 38507198)
101. Driscoll KE, Deyo LC, Carter JM, Howard BW, Hassenbein DG, Bertram TA. (1997). Effects of particle exposure and particleelicited inflammatory cells on mutation in rat alveolar epithelial cells. Carcinogenesis, 18:423-430. (Pubitemid 28134554)
102. Mühlfeld C, Gehr P, Rothen-Rutishauser B. (2008). Translocation and cellular entering mechanisms of nanoparticles in the respiratory tract. Swiss Med Wkly, 138:387-391.
103. Turco SJ. (2006). Intravenous admixtures. In: Troy BD (ed.) Remington: the science and practice of pharmacy. Lippincott Williams & Wilkins, Maryland, USA.
104. Shi Y, Porter W, Merdan T, Li LC. (2009). Recent advances in intravenous delivery of poorly water-soluble compounds. Expert Opin Drug Deliv, 6:1261-1282.
105. Akers, MJ. (2006). Parenteral preparations. In: Troy, BD (ed.) Remington: the science and practice of pharmacy. Lippincott Williams & Wilkins, Maryland, USA.
106. Yalkowsky SH, Krzyzaniak JF, Ward GH. (1998). Formulationrelated problems associated with intravenous drug delivery. J Pharm Sci, 87:787-796. (Pubitemid 28319406)
107. Wong J, Brugger A, Khare A, Chaubal M, Papadopoulos P, Rabinow B et al. (2008). Suspensions for intravenous (IV) injection: a review of development, preclinical and clinical aspects. Adv Drug Deliv Rev, 60:939-954.
108. United State Pharmacopeia (USP). The National Formulary. (2007). Particulate matter in injections.
109. Rabinow BE. (2004). Nanosuspensions in drug delivery. Nat Rev Drug Discov, 3:785-796. (Pubitemid 39242830)
110. Haley B, Frenkel E. (2008). Nanoparticles for drug delivery in cancer treatment. Urol Oncol, 26:57-64.
111. Storm G, Belliot SO, Daemen T, Lasic DD. (1995). Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliv Rev 17:31-48.
112. Cho K, Wang X, Nie S, Chen ZG, Shin DM. (2008). Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res, 14:1310-1316. (Pubitemid 351413909)
113. Davis ME, Chen ZG, Shin DM. (2008). Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov, 7:771-782.
114. Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW et al. (2006). Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA, 103:6315-6320.
115. Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME. (2007). Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci USA, 104:15549-15554. (Pubitemid 47502954)
116. Vauthier C, Dubernet C, Chauvierre C, Brigger I, Couvreur P. (2003). Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles. J Control Release, 93:151-160. (Pubitemid 37421357)
117. Schluep T, Hwang J, Cheng J, Heidel JD, Bartlett DW, Hollister B et al. (2006). Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clin Cancer Res, 12:1606-1614.
118. Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E et al. (2002). Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res, 8:1038-1044. (Pubitemid 34517637)
119. Desai NP, Soon-Shiong P, Yang, A. (2007). Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use therof. US Patent No. 0092563.
120. Desai NP, Selvaraj R, Yang A, Soon-Shiong P. (2010).compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents.US Patent No. 7771751.
121. Desai N, Trieu V, Damascelli B, Soon-Shiong P. (2009). SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients. Transl Oncol, 2:59-64.
122. Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A et al. (2006). Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res, 12:1317-1324. (Pubitemid 43342524)
123. Cortes J, Saura C. (2010). Nanoparticle albumin-bound (nab (TM))-paclitaxel: improving efficacy and tolerability by targeted drug delivery in metastatic breast cancer. EJC Suppl 8:1-10.
124. ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. (2003). Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet, 42:665-685. (Pubitemid 36936530)
125. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P et al. (2005). Phase III trial of nanoparticle albuminbound paclitaxel compared with polyethylated castor oilbased paclitaxel in women with breast cancer. J Clin Oncol, 23:7794-7803. (Pubitemid 46657376)